Elizabeth Lihua Budde, M.D., Ph.D.
- Lymphoma
- Leukemia
- Bone Marrow and Stem Cell Transplant
- Immunotherapies for Leukemia and Lymphoma
- Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
- Executive Medical Director, Enterprise Immune Effector Cell Program
Elizabeth Budde, M.D., Ph.D. is a distinguished expert in the field of hematology, specializing in treatment and research of blood malignancies. Her scholarly and clinical pursuits are dedicated to developing innovative therapies for patients battling lymphoma and leukemia. In her dual role as a physician scientist, she directs a dedicated research team in her laboratory, that designs immunotherapeutic treatments and conducts bench to bedside translation.
Dr. Budde has authored a multitude of articles in leading scientific journals such as Nature Medicine, Lancet Oncology, Journal of Clinical Oncology, Blood, Journal of Hematology & Oncology, and Clinical Cancer Research. Her work has merited her invitations to speak at various national and international conferences. As the lead investigator for several cutting-edge translational research studies, Dr. Budde actively manages a diverse array of clinical trials. She is passionately committed to extending access to the latest medical advancements to her patients, ensuring they receive the most forward-thinking care available.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
Medical Oncology
Internal Medicine
2001, M.D., Ph.D., Duke University of Medicine, Durham, NC
1995, Bachelor of Medicine, Tongji Medical University Wuhan, Hubei, China
2006-2009, University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, WA
2004-2006, Washington University School of Medicine, St. Louis, MO
2003-2004, Intern, Internal Medicine, Washington University School of Medicine, St. Louis, MO
2022-present, Executive Medical Director, Enterprise Immune Effector Cell Program
2020-present, Staff Physician and Associate Professor, Division of Lymphoma, Department of Hematologic Oncology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2013-2020, Staff Physician and Assistant Professor, Department of Hematologic Oncology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2009-2013, Acting Instructor, Department of Medicine, University of Washington, Seattle, Washington
2009-2013, Attending Physician, Hematopoietic Cell Transplant Service, Seattle Cancer Care Alliance, Seattle, Washington
2009-2013, Attending Physician, Lymphoma Clinic, Seattle Cancer Care Alliance, Seattle, Washington
Awards & Memberships
Awards
2023-2027, Clinical Investigator, California Institute for Regenerative Medicine (CIRM)
2017-2019, Clinical investigator (continuation award), Damon Runyon Cancer Research Foundation
2014-2017, Clinical investigator, Damon Runyon Cancer Research Foundation
2016, Greg Wiviott and Sharon & Robert Wiviott Seed grant, Stop Cancer Foundation
2014-2017, Clinical investigator, Damon Runyon Cancer Research Foundation
2014-2016, Tim Nesvig Lymphoma Research Foundation Fellow
2013-2016, Awardee, Developmental Research Program, City of Hope Lymphoma SPORE (P50 CA 107399)
2013-2016, Awardee, Career Enhancement Program, City of Hope Lymphoma SPORE
2013-2015, Margaret E. Early Medical Trust Fund
2013, Tower Cancer Foundation Research Grant
2010-2012, Edson Immunotherapy Pilot Award
2009-2012, Special Fellow in Clinical Research, Leukemia & Lymphoma Society
2009, Participant, AACR/ASCO Workshop in Clinical Cancer Research
2008, Participant, The 13th Annual NCCN Fellow Recognition Program
2007, Participant, AACR Workshop on Molecular Biology in Clinical Oncology Workshop
2005, Best Poster Presentation in Research Category for Medical Residents, American College of Physicians, Missouri Chapter Annual Meeting
1999, Graduate Student Travel Award, B Cell Biology, Keystone International Meeting
1997-2000, Research Assistantship, Duke University
1995-1997, Graduate School Fellowship, Duke University
1995, Graduation with Highest Honors, Tongji Medical University
Memberships
NCCN Guidelines for B Cell Lymphoma Panel
NCCN Guidelines for Management of Immunotherapy Related Toxicities Panel
AACI CAR T Working Group
Mantle Cell Lymphoma Consortium, Lymphoma Research Foundation
American Society of Hematology, Member
American Society of Clinical Oncology
Chinese American Faculty Association in Southern California (President, 2016)
Publications
- Ong, S. Y., Pak, S., Mei, M., Wang, Y., Popplewell, L., Baird, J. H., Herrera, A. F., Shouse, G., Nikolaenko, L., Zain, J., Godfrey, J., Htut, M., Aribi, A., Spielberger, R., Mansour, J., Forman, S. J., Palmer, J., & Budde, L. E. (2023). Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. American journal of hematology, 10.1002/ajh.27069. Advance online publication. https://doi.org/10.1002/ajh.27069
- Cao, Y., Marcucci, E. C., & Budde, L. E. (2023). Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting. Journal of hematology & oncology, 16(1), 69. https://doi.org/10.1186/s13045-023-01462-0
- Bartlett, N. L., Assouline, S., Giri, P., Schuster, S. J., Cheah, C. Y., Matasar, M., Gregory, G. P., Yoon, D. H., Shadman, M., Fay, K., Yoon, S. S., Panizo, C., Flinn, I., Johnston, A., Bosch, F., Sehn, L. H., Wei, M. C., Yin, S., To, I., Li, C. C., … Budde, L. E. (2023). Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood advances, 7(17), 4926–4935. https://doi.org/10.1182/bloodadvances.2022009260
- Ladbury, C., Dandapani, S., Hao, C., Fabros, M., Amini, A., Sampath, S., Glaser, S., Sokolov, K., Yeh, J., Baird, J. H., Kambhampati, S., Herrera, A., Mei, M., Nikolaenko, L., Shouse, G., & Budde, L. E. (2023). Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma. Cancers, 15(6), 1747. https://doi.org/10.3390/cancers15061747
- Strati, P., Coleman, M., Champion, R., Ma, S., Patti, C., Levy, M. Y., Lossos, I. S., Geethakumari, P. R., Lam, S., Calvo, R., Higgins, K., & Budde, L. E. (2022). A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British journal of haematology, 199(1), 76–85. https://doi.org/10.1111/bjh.18368
- Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C. Y., Wei, M. C., Yin, S., Li, C. C., Huang, H., Kwan, A., Penuel, E., & Bartlett, N. L. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. The Lancet. Oncology, 23(8), 1055–1065. https://doi.org/10.1016/S1470-2045(22)00335
- Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S. S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., Flinn, I. W., Shadman, M., Diefenbach, C., O'Hear, C., Huang, H., Kwan, A., Li, C. C., Piccione, E. C., Wei, M. C., Yin, S., … Bartlett, N. L. (2022). Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(5), 481–491. https://doi.org/10.1200/JCO.21.00931
- Dulan, S. O., Viers, K. L., Wagner, J. R., Clark, M. C., Chang, B., Gorospe, G. L., Londrc, A., Brown, A. S., Rosenthal, J., Smith, E. P., Forman, S. J., Snyder, D. S., & Budde, L. E. (2020). Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(8), 1386–1393. https://doi.org/10.1016/j.bbmt.2020.03.021
- Xue, T., & Budde, L. E. (2020). Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematology/oncology clinics of North America, 34(3), 575–587. https://doi.org/10.1016/j.hoc.2020.01.006
- Budde, L. E., Wu, D., Martin, D. B., Philip, M., Shustov, A. R., Smith, S. D., Gooley, T. A., Chen, T. L., Libby, E. N., Chen, E. Y., Kojouri, K., Langerak, A., Roden, J. E., Press, O. W., & Gopal, A. K. (2018). Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. British journal of haematology, 183(4), 601–607. https://doi.org/10.1111/bjh.15585
- Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. PMID: 33909449.
- Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. PMID: 32135517.
- Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, Deal AM, Noe JF, Ansell SM. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020 Jun 9;4(11):2548-2555. doi: 10.1182/bloodadvances.2020001871. PMID: 32516414; PMCID: PMC7284091.
- Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma. Cancer Immunol Res. 2020 Oct 22: canimm.0236.2020. doi: 10.1158/2326-6066.CIR-20-0236. Epub ahead of print. PMID: 33093217.
- Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15. PMID: 32667831; PMCID: PMC7499617.
- Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/31136781" CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019
- Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Publications Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. PMID: 30596402; PMCID: PMC6314205.
- Xue T, *Budde LE. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587. doi: 10.1016/j.hoc.2020.01.006. Epub 2020 Mar 27. PMID: 32336421. *corresponding author
- Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. PMID: 30596402; PMCID: PMC6314205.
- Dulan SO, Viers KL, Wagner JR, Clark M, Chang B, Gorospe GL, Londrc A, Brown AS, Rosenthal J, Smith EP, Forman SJ, Snyder DA, *Budde LE. Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program Biol Blood Marrow Transplant 2020;26(8):1386-1393. *corresponding author
- Xue T, *Budde LE. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587. doi: 10.1016/j.hoc.2020.01.006. Epub 2020 Mar 27. PMID: 32336421. *corresponding author
- Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. PMID: 33909449.
- Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma. Cancer Immunol Res. 2020 Oct 22: canimm.0236.2020. doi: 10.1158/2326-6066.CIR-20-0236. Epub ahead of print. PMID: 33093217.
- Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15. PMID: 32667831; PMCID: PMC7499617.
- Park SI, Shea TC, Olajide O, Reddy NM, Budde LE, Ghosh N, Deal AM, Noe JF, Ansell SM. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020 Jun 9;4(11):2548-2555. doi: 10.1182/bloodadvances.2020001871. PMID: 32516414; PMCID: PMC7284091.
- Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. PMID: 32135517.
- Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. HYPERLINK CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019 Jun;74:52-63.